Hookipa Pharma (NASDAQ:HOOK) Price Target Cut to $5.00 by Analysts at HC Wainwright

Hookipa Pharma (NASDAQ:HOOK) had its price objective reduced by equities research analysts at HC Wainwright from $6.50 to $5.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 459.72% from the company’s previous close. HC Wainwright also issued estimates for Hookipa Pharma’s Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.19) EPS.

Separately, Royal Bank of Canada reiterated an “outperform” rating and issued a $5.00 price target on shares of Hookipa Pharma in a research report on Monday, March 25th.

Hookipa Pharma Stock Performance

Shares of NASDAQ HOOK opened at $0.89 on Friday. The stock has a market cap of $88.39 million, a PE ratio of -1.02 and a beta of 1.02. Hookipa Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.05. The stock has a fifty day moving average of $0.75 and a 200-day moving average of $0.66.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $3.60 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. On average, sell-side analysts predict that Hookipa Pharma will post -0.51 EPS for the current year.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.